Vaporox

The Next Generation of Advanced Wound Care

  • Stage $3M in TTM Revenue
  • Industry Medical Devices and Equipment
  • Location Denver, CO, USA
  • Currency USD
  • Founded January 2019
  • Employees 11
  • Incorporation Type C-corp
  • Website vaporox.com

Company Summary

Vaporox, Inc.’s Vaporous Hyperoxia Therapy (VHT™), a patented, and FDA-510K-cleared technology, offers a breakthrough in treating 9 different types of skin wounds, including diabetic foot ulcers (DFUs).

Clinical trial data has shown that VHT can heal 80% or more of DFUs that have previously resisted standard wound care treatment, and at a much lower cost than less effective methods.

Team

  • Chief Executive Officer

    Alan is a Colorado native who has been an entrepreneur since college. He has founded multiple companies. His biggest “exit” was a software company, Configuresoft, which he co-founded with two of Vaporox’s BOD members, Louis Woodhill and Alex Goldstein.

  • Loren Hutchins
    Chief Product Officer

    Loren has worked in machine design and automated equipment development since 1994 and has specialized in medical devices for the past two decades. He was the lead product specialist at Baxa Corporation, which was acquired by Baxter International.

  • Vice President of Sales

    Commercial executive with over 17 years of high performance leadership experience in the medical device industry. I have developed and executed effective sales and marketing strategies for various market segments, including interventional radiology, nephrology, vascular surgery, pediatric nephrology, orthopedics, capital equipment, and disposables.

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free